• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Immunome, Inc. - Common Stock (NQ:IMNM)

    20.95 -1.57 (-6.97%)
    Streaming Delayed Price Updated: 4:00 PM EST, Mar 5, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 2,243,162
    Open 22.01
    Bid (Size) 20.75 (600)
    Ask (Size) 20.91 (100)
    Prev. Close 22.52
    Today's Range 20.66 - 22.24
    52wk Range 5.150 - 27.65
    Shares Outstanding 87,012,328
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Immunome, Inc.
    Via Business Wire
    News headline image
    Investment Manager Fully Exits Immunome Stock in $37.3 Million Sale, According to Latest SEC Filing ↗
    Immunome develops antibody therapeutics for cancer and infectious diseases, reporting a market cap above $2 billion in the latest filing. 
    Via The Motley Fool
    Topics Regulatory Compliance

    Performance

    YTD
    +0.6%
    +0.6%
    1 Month
    -22.3%
    -22.3%
    3 Month
    +4.3%
    +4.3%
    6 Month
    +113.8%
    +113.8%
    1 Year
    +125.0%
    +125.0%

    More News

    Read More
    News headline image
    Immunome Reports Full Year 2025 Financial Results and Provides Business Update
    From Immunome, Inc.
    Via Business Wire
    News headline image
    Immunome to Present at Upcoming Investor Conferences
    From Immunome, Inc.
    Via Business Wire
    News headline image
    Nurix Stock Is Down 6% This Past Year, but One Biotech Fund Still Boosted Its Bet By $63 Million ↗
    Via The Motley Fool
    News headline image
    Biotech-Focused Fund Adds $12 Million to Immunome Bet as Stock Surges 120% ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Investor Slashes $70 Million From Zymeworks as Stock Jumps 60% in a Year ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Biotech Investor Adds $3 Million to Krystal Biotech as Revenue Hits $389 Million in 2025 ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Biotech Fund Doubles Down With $49 Million Scholar Rock Buy as Shares Climb 26% ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Immunome, Inc.
    Via Business Wire
    News headline image
    The $71 Billion Cancer Shift: Why The FDA Is Speeding Up
    From Equity Insider
    Via GlobeNewswire
    News headline image
    Immunome to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
    From Immunome, Inc.
    Via Business Wire
    News headline image
    Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Immunome, Inc.
    Via Business Wire
    News headline image
    Immunome to Present at 44th Annual J.P. Morgan Healthcare Conference
    From Immunome, Inc.
    Via Business Wire
    News headline image
    Immunome Announces Pricing of Public Offering of Common Stock
    From Immunome, Inc.
    Via Business Wire
    News headline image
    Why Immunome Stock Surged Today ↗
    Via The Motley Fool
    News headline image
    Immunome Announces Proposed Public Offering of Common Stock
    From Immunome, Inc.
    Via Business Wire
    News headline image
    Cancer Drug Developers Secure Regulatory Clarity as FDA Reshapes Approval Standards
    From Equity Insider
    Via GlobeNewswire
    News headline image
    ENDRA Life Sciences (NASDAQ: NDRA) Advances Health Tech (Alongside KYTX, RADX, GLSI IMNM) With a Next-Generation Treasury Strategy
    Via AB Newswire
    News headline image
    Which stocks are gapping on Monday? ↗
    Via Chartmill
    News headline image
    Why Is IMNM Stock Rising Today? ↗
    Via Stocktwits
    News headline image
    Immunome Announces Positive Topline Results from Phase 3 RINGSIDE Trial of Varegacestat in Patients with Desmoid Tumors
    From Immunome, Inc.
    Via Business Wire
    News headline image
    Immunome to Announce Topline Results from Phase 3 RINGSIDE Trial of Varegacestat in Patients with Desmoid Tumors
    From Immunome, Inc.
    Via Business Wire
    News headline image
    Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Immunome, Inc.
    Via Business Wire
    News headline image
    Immunome to Present at Upcoming Investor Conferences
    From Immunome, Inc.
    Via Business Wire

    Frequently Asked Questions

    Is Immunome, Inc. - Common Stock publicly traded?
    Yes, Immunome, Inc. - Common Stock is publicly traded.
    What exchange does Immunome, Inc. - Common Stock trade on?
    Immunome, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Immunome, Inc. - Common Stock?
    The ticker symbol for Immunome, Inc. - Common Stock is IMNM on the Nasdaq Stock Market
    What is the current price of Immunome, Inc. - Common Stock?
    The current price of Immunome, Inc. - Common Stock is 20.95
    When was Immunome, Inc. - Common Stock last traded?
    The last trade of Immunome, Inc. - Common Stock was at 03/05/26 04:00 PM ET
    What is the market capitalization of Immunome, Inc. - Common Stock?
    The market capitalization of Immunome, Inc. - Common Stock is 1.82B
    How many shares of Immunome, Inc. - Common Stock are outstanding?
    Immunome, Inc. - Common Stock has 2B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.